Evommune, Inc.
EVMN- 1M
- -29.1%
Evommune, Inc. in brief
Evommune, Inc. is a listed company in the Biotechnology industry, based in Palo Alto, California, USA. Its market value was $282 M on 30 October 2026, which makes it the 15,028th largest listed company in the world and the 2,931st largest in the USA on this site. In the year to December 2025 it had sales of $13 M and a net loss of $69 M. It employs about 48 people and Luis C. Pena is its chief executive. Its shares trade under the symbol EVMN (NYSE).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Evommune, Inc.
Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis and ulcerative colitis. Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.
From the company's annual report filed with the US SEC: read the report
Evommune, Inc. timeline
- 2025
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 🔔Initial public offering on NYSEFinal prospectus filed with the SEC on 6 November 2025; shares registered for exchange trading on 4 November 2025.
Events of Evommune, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #2,498 (Aug 2026) · #2,665 (Sep 2026) · #2,935 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- 21.7×
- Price / book
- 1.4×
- Free cash flow yield
- -27.2%
- Net margin
- -529.8%
- Operating margin
- -623.6%
- Return on equity
- -33.5%
- Liabilities / assets
- 8.6%
- Revenue growth
- +85.7%
- R&D / revenue
- 569.5%
- Revenue per employee
- $271 K
- Profit per employee
- $-1.4 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $13M | +85.7% | $-81M | $-69M | -529.8% |
| Dec 2024 | $7M | — | $-70M | $-67M | -954.4% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-76M | $0M | $-77M | $-11.22 | — |
| Dec 2024 | $-58M | $0M | $-58M | $-45.29 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-31M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Nov 12, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Nov 5, 20268-KCurrent reportRegulation FD disclosure
- Nov 4, 20268-KCurrent reportMaterial agreement · Unregistered share sale · Regulation FD disclosure · Other events
- Oct 1, 20268-KCurrent reportRegulation FD disclosure
- Sep 23, 20268-KCurrent reportRegulation FD disclosure
- Sep 15, 20268-KCurrent reportRegulation FD disclosure
- Sep 9, 20268-KCurrent reportRegulation FD disclosure · Other events
- Aug 6, 202610-QQuarterly report · period to Jun 2026
- Aug 6, 20268-KCurrent reportResults of operations
- Jul 30, 20268-KCurrent reportRegulation FD disclosure
- Jun 29, 20268-KCurrent reportRegulation FD disclosure · Other events
Official filings of Evommune, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $13 M
- Operating income
- $-81 M
- Net income
- $-69 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $225 M
- Total liabilities
- $19 M
- Total equity
- $206 M
As of December-2025
Top 100 institutional investors in Evommune, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | EQT Fund Management S.a r.l. | 5,288,313 | 0 (0.00%) | 12.79% | $44 M | Nov 12, 2026 |
| 2 | Ra Capital Management, L.P. | 3,494,638 | 0 (0.00%) | 8.45% | $29 M | Nov 16, 2026 |
| 3 | Point72 Asset Management, L.P. | 2,434,080 | +999,031 (+69.62%) | 5.89% | $20 M | Nov 16, 2026 |
| 4 | Pivotal bioVenture Partners Investment Advisor LLC | 1,926,943 | 0 (0.00%) | 4.66% | $16 M | Nov 13, 2026 |
| 5 | Nan Fung Group Holdings Ltd | 1,441,032 | 0 (0.00%) | 3.48% | $12 M | Nov 13, 2026 |
| 6 | Defilade Capital Management, L.P. | 1,430,573 | +637,428 (+80.37%) | 3.46% | $12 M | Nov 16, 2026 |
| 7 | Vestal Point Capital, LP | 1,250,000 | +250,000 (+25.00%) | 3.02% | $10 M | Nov 16, 2026 |
| 8 | Baker Bros. Advisors LP | 1,234,794 | +387,404 (+45.72%) | 2.99% | $10 M | Nov 16, 2026 |
| 9 | Kynam Capital Management, LP | 1,200,000 | New | 2.90% | $10 M | Nov 16, 2026 |
| 10 | BlackRock, Inc. | 1,154,070 | +267,532 (+30.18%) | 2.79% | $10 M | Nov 13, 2026 |
| 11 | Vanguard Capital Management LLC | 1,004,473 | +122,578 (+13.90%) | 2.43% | $8 M | Nov 13, 2026 |
| 12 | Price T Rowe Associates Inc /MD/ | 851,866 | -1,089,073 (-56.11%) | 2.06% | $7 M | Nov 16, 2026 |
| 13 | Millennium Management LLC | 847,296 | New | 2.05% | $7 M | Nov 16, 2026 |
| 14 | American Century Companies Inc | 762,340 | +7,322 (+0.97%) | 1.84% | $6 M | Nov 12, 2026 |
| 15 | Qube Research & Technologies Ltd | 684,713 | +654,598 (+2173.66%) | 1.66% | $6 M | Nov 13, 2026 |
| 16 | Silverarc Capital Management, LLC | 594,027 | New | 1.44% | $5 M | Nov 12, 2026 |
| 17 | Barclays PLC | 526,560 | +347,830 (+194.61%) | 1.27% | $4 M | Nov 6, 2026 |
| 18 | Geode Capital Management, LLC | 467,271 | +165,512 (+54.85%) | 1.13% | $4 M | Nov 6, 2026 |
| 19 | Velan Capital Investment Management LP | 456,255 | +5,000 (+1.11%) | 1.10% | $4 M | Nov 16, 2026 |
| 20 | Sphera Funds Management LTD. | 390,632 | +368,000 (+1626.02%) | 0.94% | $3 M | Nov 16, 2026 |
| 21 | Citadel Advisors LLC | 379,729 | +369,005 (+3440.93%) | 0.92% | $3 M | Nov 16, 2026 |
| 22 | Jane Street Group, LLC | 330,031 | +97,591 (+41.99%) | 0.80% | $3 M | Nov 12, 2026 |
| 23 | Great Point Partners LLC | 325,000 | 0 (0.00%) | 0.79% | $3 M | Nov 16, 2026 |
| 24 | Goldman Sachs Group Inc | 301,400 | +108,405 (+56.17%) | 0.73% | $2 M | Nov 16, 2026 |
| 25 | Trexquant Investment LP | 284,954 | New | 0.69% | $2 M | Nov 16, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | State Street Corp | 267,910 | -25,606 (-8.72%) | 0.65% | $2 M | Nov 12, 2026 |
| 27 | Two Sigma Investments, LP | 259,835 | +234,309 (+917.92%) | 0.63% | $2 M | Nov 16, 2026 |
| 28 | Cantor Fitzgerald, L. P. | 257,505 | +153,913 (+148.58%) | 0.62% | $2 M | Nov 16, 2026 |
| 29 | BNP Paribas Financial Markets | 243,511 | +110,161 (+82.61%) | 0.59% | $2 M | Nov 12, 2026 |
| 30 | RTW Investments, LP | 208,071 | -1,294,164 (-86.15%) | 0.50% | $2 M | Nov 16, 2026 |
| 31 | SummitTX Capital, L.P. | 201,714 | New | 0.49% | $2 M | Nov 16, 2026 |
| 32 | FMR LLC | 168,774 | +168,610 (+102810.98%) | 0.41% | $1 M | Nov 10, 2026 |
| 33 | XTX Topco Ltd | 166,671 | +105,977 (+174.61%) | 0.40% | $1 M | Nov 16, 2026 |
| 34 | Orbimed Advisors LLC | 161,000 | 0 (0.00%) | 0.39% | $1 M | Nov 16, 2026 |
| 35 | Y-Intercept (Hong Kong) Ltd | 158,813 | +130,415 (+459.24%) | 0.38% | $1 M | Oct 16, 2026 |
| 36 | Nuveen, LLC | 158,160 | +137,261 (+656.78%) | 0.38% | $1 M | Nov 10, 2026 |
| 37 | Vanguard Fiduciary Trust Co | 152,823 | +64,624 (+73.27%) | 0.37% | $1 M | Nov 13, 2026 |
| 38 | Charles Schwab Investment Management Inc | 150,907 | +17,835 (+13.40%) | 0.36% | $1 M | Nov 16, 2026 |
| 39 | Northern Trust Corp | 136,970 | +35,566 (+35.07%) | 0.33% | $1 M | Nov 16, 2026 |
| 40 | Vanguard Portfolio Management LLC | 136,265 | +16,338 (+13.62%) | 0.33% | $1 M | Nov 13, 2026 |
| 41 | HRT Financial LP | 127,306 | New | 0.31% | $1 M | Nov 13, 2026 |
| 42 | NEXTBio Capital Management LP | 119,063 | 0 (0.00%) | 0.29% | $1 M | Nov 13, 2026 |
| 43 | D. E. Shaw & Co., Inc. | 99,944 | New | 0.24% | $1 M | Nov 16, 2026 |
| 44 | Andera Partners | 97,362 | -1,294,628 (-93.01%) | 0.24% | $1 M | Oct 16, 2026 |
| 45 | Morgan Stanley | 94,573 | -195,601 (-67.41%) | 0.23% | $1 M | Nov 13, 2026 |
| 46 | Jump Financial, LLC | 84,023 | +53,823 (+178.22%) | 0.20% | $1 M | Nov 13, 2026 |
| 47 | ADAR1 Capital Management, LLC | 82,350 | -21,685 (-20.84%) | 0.20% | $1 M | Nov 16, 2026 |
| 48 | Squarepoint Ops LLC | 79,696 | +31,994 (+67.07%) | 0.19% | $1 M | Nov 9, 2026 |
| 49 | Walleye Capital LLC | 78,967 | New | 0.19% | $1 M | Nov 13, 2026 |
| 50 | Marshall Wace, LLP | 76,811 | New | 0.19% | $1 M | Nov 13, 2026 |
| 51 | Seven Grand Managers, LLC | 50,000 | -40,568 (-44.79%) | 0.12% | $0 M | Nov 16, 2026 |
| 52 | Algert Global LLC | 48,814 | New | 0.12% | $0 M | Nov 17, 2026 |
| 53 | Alps Advisors Inc | 47,737 | +11,179 (+30.58%) | 0.12% | $0 M | Nov 3, 2026 |
| 54 | Atom Investors LP | 42,125 | New | 0.10% | $0 M | Nov 16, 2026 |
| 55 | TD Asset Management Inc | 40,394 | -20,268 (-33.41%) | 0.10% | $0 M | Nov 13, 2026 |
| 56 | Jpmorgan Chase & Co | 40,065 | -1,513,067 (-97.42%) | 0.10% | $0 M | Nov 12, 2026 |
| 57 | Silverback Asset Management LLC | 40,000 | New | 0.10% | $0 M | Nov 16, 2026 |
| 58 | Balyasny Asset Management L.P. | 35,868 | -421,147 (-92.15%) | 0.09% | $0 M | Nov 16, 2026 |
| 59 | Bank Of America Corp /de/ | 35,085 | +24,217 (+222.83%) | 0.08% | $0 M | Nov 16, 2026 |
| 60 | Bank of New York Mellon Corp | 28,911 | +3,360 (+13.15%) | 0.07% | $0 M | Nov 5, 2026 |
| 61 | Manufacturers Life Insurance Company, The | 27,289 | -11,619 (-29.86%) | 0.07% | $0 M | Nov 13, 2026 |
| 62 | Vestcor Inc | 24,570 | New | 0.06% | $0 M | Nov 12, 2026 |
| 63 | Schonfeld Strategic Advisors LLC | 21,450 | New | 0.05% | $0 M | Nov 16, 2026 |
| 64 | UBS Group AG | 20,970 | -392,583 (-94.93%) | 0.05% | $0 M | Nov 10, 2026 |
| 65 | US Bancorp \de\ | 19,000 | New | 0.05% | $0 M | Nov 5, 2026 |
| 66 | Axq Capital, LP | 16,864 | New | 0.04% | $0 M | Nov 12, 2026 |
| 67 | Virtus Investment Advisers, LLC | 16,003 | -497 (-3.01%) | 0.04% | $0 M | Nov 12, 2026 |
| 68 | Alliancebernstein L.P. | 15,760 | 0 (0.00%) | 0.04% | $0 M | Nov 16, 2026 |
| 69 | Canada Pension Plan Investment Board | 15,200 | New | 0.04% | $0 M | Nov 16, 2026 |
| 70 | Rhumbline Advisers | 14,805 | +310 (+2.14%) | 0.04% | $0 M | Nov 10, 2026 |
| 71 | Susquehanna International Group, LLP | 13,920 | +736 (+5.58%) | 0.03% | $0 M | Nov 16, 2026 |
| 72 | Deutsche Bank AG\ | 11,085 | -1,526 (-12.10%) | 0.03% | $0 M | Nov 6, 2026 |
| 73 | Vanguard Global Advisers, LLC | 8,679 | +4,919 (+130.82%) | 0.02% | $0 M | Nov 13, 2026 |
| 74 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 7,388 | +1,550 (+26.55%) | 0.02% | $0 M | Nov 16, 2026 |
| 75 | Wells Fargo & Company/mn | 4,709 | -7,357 (-60.97%) | 0.01% | $0 M | Nov 16, 2026 |
| 76 | New York State Common Retirement Fund | 4,300 | 0 (0.00%) | 0.01% | $0 M | Nov 17, 2026 |
| 77 | Russell Investments Group, Ltd. | 4,152 | -43 (-1.03%) | 0.01% | $0 M | Nov 6, 2026 |
| 78 | Natixis | 3,365 | -1,679 (-33.29%) | 0.01% | $0 M | Nov 6, 2026 |
| 79 | Police & Firemen's Retirement System of New Jersey | 3,006 | 0 (0.00%) | 0.01% | $0 M | Nov 9, 2026 |
| 80 | Citigroup Inc | 1,926 | -4,326 (-69.19%) | 0.00% | $0 M | Nov 4, 2026 |
| 81 | Group One Trading LLC | 1,900 | New | 0.00% | $0 M | Nov 10, 2026 |
| 82 | Caitong International Asset Management Co., Ltd | 1,561 | +1,272 (+440.14%) | 0.00% | $0 M | Oct 29, 2026 |
| 83 | Tower Research Capital LLC (TRC) | 1,484 | -1,388 (-48.33%) | 0.00% | $0 M | Nov 16, 2026 |
| 84 | Legal & General Group Plc | 1,231 | -7,290 (-85.55%) | 0.00% | $0 M | Nov 16, 2026 |
| 85 | Royal Bank Of Canada | 919 | +227 (+32.80%) | 0.00% | $0 M | Nov 16, 2026 |
| 86 | Ameritas Investment Partners, Inc. | 855 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 87 | State of Wyoming | 554 | -284 (-33.89%) | 0.00% | $0 M | Oct 28, 2026 |
| 88 | Global Retirement Partners, LLC | 552 | New | 0.00% | $0 M | Nov 10, 2026 |
| 89 | Sterling Capital Management LLC | 416 | +371 (+824.44%) | 0.00% | $0 M | Oct 22, 2026 |
| 90 | PNC Financial Services Group, Inc. | 351 | +259 (+281.52%) | 0.00% | $0 M | Nov 6, 2026 |
| 91 | Nisa Investment Advisors, LLC | 300 | +271 (+934.48%) | 0.00% | $0 M | Oct 20, 2026 |
| 92 | Farther Finance Advisors, LLC | 265 | New | 0.00% | $0 M | Oct 8, 2026 |
| 93 | GAMMA Investing LLC | 231 | +207 (+862.50%) | 0.00% | $0 M | Oct 8, 2026 |
| 94 | Simplex Trading, LLC | 208 | New | 0.00% | $0 M | Nov 4, 2026 |
| 95 | MassMutual Private Wealth & Trust, FSB | 203 | New | 0.00% | $0 M | Oct 5, 2026 |
| 96 | Arax Advisory Partners | 164 | +163 (+16300.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 97 | California State Teachers Retirement System | 147 | -11,513 (-98.74%) | 0.00% | $0 M | Nov 13, 2026 |
| 98 | Quarry LP | 122 | +57 (+87.69%) | 0.00% | $0 M | Nov 16, 2026 |
| 99 | Osaic Holdings, Inc. | 80 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 100 | EverSource Wealth Advisors, LLC | 28 | New | 0.00% | $0 M | Nov 4, 2026 |
Mutual funds holding Evommune, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Eventide Healthcare & Life Sciences FundEventide Asset Management, LLC | 940,119 | $12 M | 2.3% | 0.70% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 739,068 | $10 M | 1.8% | <0.01% | +132% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price New Horizons Fund, Inc.T. Rowe Price Associates, Inc. | 711,122 | $9 M | 1.7% | 0.06% | +96% | Jun 30, 2026 |
| 🇺🇸 JPMorgan Small Cap Growth FundJ.P. Morgan Investment Management Inc. | 554,355 | $7 M | 1.3% | 0.28% | −9.9% | Jun 30, 2026 |
| 🇺🇸 Small Cap Growth FundAmerican Century Investment Management, Inc. | 567,828 | $6 M | 1.4% | 0.11% | +51% | Jul 31, 2026 |
| 🇺🇸 T. Rowe Price Health Sciences Fund, Inc.T. Rowe Price Associates, Inc. | 346,633 | $5 M | 0.84% | 0.04% | +41% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 332,110 | $4 M | 0.80% | <0.01% | +37% | Jun 30, 2026 |
| 🇺🇸 Federated Hermes Kaufmann Small Cap FundFederated Advisory Services Company | 325,000 | $4 M | 0.79% | 0.13% | no change | Jul 31, 2026 |
| 🇺🇸 T. Rowe Price Integrated U.S. Small-Cap Growth Equity FundT. Rowe Price Associates, Inc. | 258,200 | $3 M | 0.62% | 0.03% | +53% | Jun 30, 2026 |
| 🇺🇸 JPMorgan Small Cap Blend FundJ.P. Morgan Investment Management Inc. | 176,234 | $2 M | 0.43% | 0.14% | −11% | Jun 30, 2026 |
| 🇺🇸 Multi-Manager Small Cap Equity Strategies FundColumbia Funds Series Trust I | 92,684 | $2 M | 0.22% | 0.17% | +1.4% | May 31, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 126,549 | $2 M | 0.31% | <0.01% | +1.3% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 119,063 | $2 M | 0.29% | 0.01% | +169% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 138,618 | $2 M | 0.34% | <0.01% | +33% | Jul 31, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 58,033 | $1 M | 0.14% | <0.01% | +19% | May 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 53,877 | $1 M | 0.13% | <0.01% | +452% | May 31, 2026 |
| 🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc. | 53,264 | $1 M | 0.13% | <0.01% | +19% | May 31, 2026 |
| 🇺🇸 Small Cap Growth FundThe Variable Annuity Life Insurance Company | 38,499 | $1 M | 0.09% | 0.17% | no change | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 42,650 | $1 M | 0.10% | 0.04% | +61% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Mid Cap ETFT. Rowe Price Associates, Inc. | 40,640 | $1 M | 0.10% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 20,417 | $0 M | 0.05% | <0.01% | +12% | May 31, 2026 |
| 🇺🇸 T. Rowe Price Integrated U.S. Small-Mid Cap Core Equity FundT. Rowe Price Associates, Inc. | 29,866 | $0 M | 0.07% | 0.02% | +6.4% | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 17,018 | $0 M | 0.04% | <0.01% | −3.4% | May 31, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 30,830 | $0 M | 0.07% | <0.01% | +34% | Jul 31, 2026 |
| 🇺🇸 T.Rowe Price Small Cap Growth PortfolioBrighthouse Investment Advisers, LLC | 25,200 | $0 M | 0.06% | 0.03% | +44% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Health Sciences PortfolioT. Rowe Price Associates, Inc. | 23,915 | $0 M | 0.06% | 0.04% | +46% | Jun 30, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 23,699 | $0 M | 0.06% | <0.01% | +40% | Jun 30, 2026 |
| 🇺🇸 Small Company Growth PortfolioThe Vanguard Group, Inc. | 19,515 | $0 M | 0.05% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Transamerica T. Rowe Price Small Cap VPTransamerica Asset Management, Inc. | 18,900 | $0 M | 0.05% | 0.03% | +80% | Jun 30, 2026 |
| 🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC | 15,368 | $0 M | 0.04% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 16,861 | $0 M | 0.04% | <0.01% | +35% | Jul 31, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 13,871 | $0 M | 0.03% | <0.01% | +32% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 11,880 | $0 M | 0.03% | 0.01% | +184% | Jun 30, 2026 |
| 🇺🇸 Column Small Cap FundTrust for Professional Managers | 6,194 | $0 M | 0.01% | 0.03% | no change | May 31, 2026 |
| 🇺🇸 Schwab U.S. Broad Market ETFCharles Schwab Investment Management, Inc. | 6,000 | $0 M | 0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 12,000 | $0 M | 0.03% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 9,814 | $0 M | 0.02% | <0.01% | +61% | Jun 30, 2026 |
| 🇺🇸 Gabelli Healthcare & WellnessRx TrustGabelli Funds, LLC | 9,500 | $0 M | 0.02% | 0.08% | +100% | Jun 30, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 9,300 | $0 M | 0.02% | <0.01% | +35% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc. | 5,125 | $0 M | 0.01% | <0.01% | +425% | May 31, 2026 |
| 🇺🇸 Health Sciences TrustJohn Hancock Variable Trust Advisers LLC | 8,201 | $0 M | 0.02% | 0.04% | +48% | Jun 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 8,180 | $0 M | 0.02% | <0.01% | +169% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 4,321 | $0 M | 0.01% | <0.01% | new | May 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc. | 3,866 | $0 M | <0.01% | <0.01% | +1123% | May 31, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 6,535 | $0 M | 0.02% | <0.01% | +22% | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 6,464 | $0 M | 0.02% | <0.01% | +25% | Jun 30, 2026 |
| 🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION | 3,500 | $0 M | <0.01% | <0.01% | new | May 31, 2026 |
| 🇺🇸 Goldman Sachs Small Cap Value Insights FundGoldman Sachs Asset Management, L.P. | 7,036 | $0 M | 0.02% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 EQ/T.Rowe Price Health Sciences PortfolioEquitable Investment Management Group, LLC | 5,933 | $0 M | 0.01% | 0.04% | +48% | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 5,273 | $0 M | 0.01% | <0.01% | +23% | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 5,140 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 6,073 | $0 M | 0.01% | <0.01% | +33% | Jul 31, 2026 |
| 🇺🇸 iShares Morningstar Small-Cap Growth ETFBlackRock Fund Advisors | 5,847 | $0 M | 0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 5,757 | $0 M | 0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Fidelity MSCI Health Care Index ETFFidelity Management & Research Company LLC | 5,133 | $0 M | 0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 4,200 | $0 M | 0.01% | <0.01% | +17% | Jun 30, 2026 |
| 🇺🇸 Tiff Multi-Asset FundTIFF Advisory Services, LLC | 4,165 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 3,861 | $0 M | <0.01% | <0.01% | +40% | Jun 30, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 3,500 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC | 3,986 | $0 M | <0.01% | <0.01% | +2.7% | Jul 31, 2026 |
| 🇺🇸 Goldman Sachs Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P. | 3,849 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Goldman Sachs Variable Insurance Trust Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P. | 3,140 | $0 M | <0.01% | 0.02% | no change | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 2,876 | $0 M | <0.01% | 0.02% | +55% | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 2,811 | $0 M | <0.01% | <0.01% | +40% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 2,665 | $0 M | <0.01% | <0.01% | +38% | Jun 30, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC | 2,137 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 FlexShares Morningstar US Market Factor Tilt Index FundNorthern Trust Investments, Inc. | 2,528 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 1,991 | $0 M | <0.01% | <0.01% | +37% | Jun 30, 2026 |
| 🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 1,918 | $0 M | <0.01% | <0.01% | +164% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 1,911 | $0 M | <0.01% | <0.01% | +65% | Jun 30, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 2,219 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 1,806 | $0 M | <0.01% | <0.01% | +40% | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Small Cap Growth Insights FundGoldman Sachs Asset Management, L.P. | 2,056 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC | 1,912 | $0 M | <0.01% | <0.01% | +13% | Jul 31, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 1,601 | $0 M | <0.01% | <0.01% | +45% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc. | 888 | $0 M | <0.01% | <0.01% | +380% | May 31, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 1,717 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 1,485 | $0 M | <0.01% | <0.01% | +31% | Jul 31, 2026 |
| 🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC | 1,153 | $0 M | <0.01% | 0.01% | +142% | Jun 30, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 1,013 | $0 M | <0.01% | <0.01% | +29% | Jun 30, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC | 1,002 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 1,156 | $0 M | <0.01% | <0.01% | +42% | Jul 31, 2026 |
| 🇺🇸 NVIT GS Small Cap Equity Insights FundNATIONWIDE FUND ADVISORS | 918 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC | 888 | $0 M | <0.01% | <0.01% | +39% | Jun 30, 2026 |
| 🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC | 492 | $0 M | <0.01% | <0.01% | new | May 31, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 855 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC | 970 | $0 M | <0.01% | <0.01% | +116% | Jul 31, 2026 |
| 🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC | 811 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Strategic Allocation: Aggressive FundAmerican Century Strategic Asset Allocations Inc | 950 | $0 M | <0.01% | <0.01% | +26% | Jul 31, 2026 |
| 🇺🇸 iShares Morningstar Small-Cap ETFBlackRock Fund Advisors | 831 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC | 388 | $0 M | <0.01% | <0.01% | new | May 31, 2026 |
| 🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC | 384 | $0 M | <0.01% | <0.01% | new | May 31, 2026 |
| 🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC | 611 | $0 M | <0.01% | <0.01% | −7.3% | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 575 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 543 | $0 M | <0.01% | <0.01% | +71% | Jun 30, 2026 |
| 🇺🇸 Strategic Allocation: Moderate FundAmerican Century Strategic Asset Allocations Inc | 630 | $0 M | <0.01% | <0.01% | +1.9% | Jul 31, 2026 |
| 🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC | 248 | $0 M | <0.01% | <0.01% | new | May 31, 2026 |
| 🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC | 274 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc. | 248 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 21 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Evommune, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Luis C. PenaPresident & CEO, Director | Grant or award | +1,115 | $7.020 | $8 K | 631,573 | Form 4 |
| filed | Kyle CarverChief Financial Officer | Buy | +1,000 | $13.26 | $13 K | 60,335 | Form 4 |
| filed | Arthur S. KirschDirector | Buyindirect | +10,000 | $13.30 | $133 K | 10,000 | Form 4 |
| filed | Jeegar Pravinkumar PatelChief Scientific Officer | Option exercise10b5-1 plan | +1,488 | $3.840 | $6 K | 47,891 | Form 4 |
| filed | Luis C. PenaPresident & CEO, Director | Sell10b5-1 plan | -7,438 | $22.71 | $169 K | 630,458 | Form 4 |
| filed | Janice Suzann DrewChief of Dev. Operations | Option exercise10b5-1 plan | +3,839 | $3.840 | $15 K | 71,633 | Form 4 |
| filed | Jeegar Pravinkumar PatelChief Scientific Officer | Sell10b5-1 plan | -1,488 | $22.50 | $33 K | 46,403 | Form 4 |
| filed | Janice Suzann DrewChief of Dev. Operations | Option exercise10b5-1 plan | +16,161 | $2.990 | $48 K | 87,794 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Evommune, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
IPO: priced at $16.00, raising $150M · IPO calendar
Stock splits: 1-for-8.52 reverse split
Fails to deliver
- : 7,646 shares at $6.81
- : 16 shares at $9.60
- : 379 shares at $13.23
- : 5 shares at $15.01
- : 5,581 shares at $13.38
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Evommune, Inc. scorecard#
Passes 4 of the 13 checks that could be worked out: strongest in valuation (1 of 5), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 30, 2026.
Valuation1 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median1.4×Price to book 1.4× against Biotechnology's median of 2.9×.
- ✗Price to sales below its peers' median21.7×Price to sales 21.7× against Biotechnology's median of 8.7×.
- ✗Free cash flow yield above 5%-27.2%Free cash flow is -27.2% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth1 of 2
- ✓Revenue grew in the newest year85.7%Revenue up 85.7% in fiscal 2025.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-11.22 vs -45.29Diluted EPS -11.22 in fiscal 2025 against -45.29 the year before (report's currency).
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$69 MNet income -$69 M in fiscal 2025.
- –Profitable in each of the last five yearsFive years of net income are not on file.
- ✗Operating margin above its peers' median-623.6%-623.6% against Biotechnology's median of -60.5% (243 companies).
- ✗Return on equity above 15%-224.6%-224.6% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health2 of 2
- ✓Short-term assets cover short-term liabilities8.6×Current ratio 8.57 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- –Cash from operations positive in each of the last three yearsThree years of operating cash flow are not on file.
- ✓Altman Z-score outside the distress zone6.93Z-score 6.93 (safe zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year307.0%Diluted shares up 307.0% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Evommune, Inc.'s statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -623.6% | -60.5% | |
| Net margin | -529.8% | -68.9% | |
| Return on equity | -224.6% | -61.0% | |
| Revenue growth | 85.7% | 15.8% | |
| Free cash flow margin | -589.9% | -61.5% |
2of 7on the Piotroski tests of financial strength
- Net loss of $69 million.
- Free cash flow was negative: -$77 million.
- The share count rose 307.0% in the year.
Evommune, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 |
|---|---|---|---|
| Income statement | |||
| Revenue | 13+85.7%100% | 7.0—100% | |
| Research and development | 74+15.3%570% | 64—918% | |
| General and administrative | 20+56.9%154% | 13—182% | |
| Operating expenses | 94+22.1%724% | 77—1100% | |
| Operating income | −81—−624% | −70—−1000% | |
| Interest and finance income | 3.3+2.5%25.6% | 3.2—46.3% | |
| Other non-operating income (expense) | 12+281%93.9% | 3.2—45.8% | |
| Income before tax | −69—−530% | −68—−976% | |
| Income tax | 0—0.0% | 0—0.0% | |
| Net income including minority interests | −69—−530% | −67—−954% | |
| Net income attributable to shareholders | −69—−530% | −67—−954% | |
| Earnings per share, basic | -11.22—— | -45.29—— | |
| Earnings per share, diluted | -11.22—— | -45.29—— | |
| Shares, weighted average (basic) | 6.1+307%— | 1.5—— | |
| Shares, weighted average (diluted) | 6.1+307%— | 1.5—— | |
| Balance sheet | |||
| Cash and cash equivalents | 44+171%19.6% | 16—21.4% | |
| Short-term investments | 105+88.5%46.7% | 56—73.3% | |
| Other current assets | 4.3+120%1.9% | 1.9—2.6% | |
| Current assets | 153+107%68.2% | 74—97.3% | |
| Property, plant and equipment | 1.0−25.0%0.4% | 1.3—1.7% | |
| Right-of-use (leased) assets | 1.5+211%0.7% | 0.5—0.6% | |
| Long-term investments | 67—30.0% | — | |
| Total assets | 225+196%100% | 76—100% | |
| Accounts payable | 7.8−6.1%3.4% | 8.3—10.9% | |
| Current liabilities | 18−36.0%8.0% | 28—36.8% | |
| Lease liabilities (non-current) | 1.3—0.6% | — | |
| Total liabilities | 19−32.0%8.6% | 29—37.5% | |
| Retained earnings | −221—−98.3% | −152—−200% | |
| Shareholders' equity | 206—91.4% | −144—−190% | |
| Total liabilities and equity | 225+196%100% | 76—100% | |
| Shares outstanding | 32+1932%— | 1.6—— | |
| Cash-flow statement | |||
| Depreciation and amortization | 0.6+20.0%4.6% | 0.5—7.1% | |
| Share-based compensation | 5.9+240%45.0% | 1.7—24.6% | |
| Cash from operating activities | −76—−588% | −58—−831% | |
| Capital expenditure | −0.2—−1.8% | −0.1—−1.3% | |
| Cash from investing activities | −115—−887% | −4.0—−57.0% | |
| Cash from financing activities | 221+347%1698% | 49—706% | |
| Change in cash | 29—223% | −13—−182% | |
| Report | 10-K | 10-K | |
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 0—— | 0−100%— | 0—— | 0—— | 0*—— | 10—100% | |
| Research and development | 89—— | 25+25.0%— | 26—— | 17—— | 20*—— | 20—196% | |
| General and administrative | 33—— | 8.8+138%— | 8.5—— | 6.6—— | 9.3*—— | 3.7—36.9% | |
| Operating expenses | 122—— | 33+42.9%— | 35—— | 24—— | 30*—— | 23—233% | |
| Operating income | −122—— | −33—— | −35—— | −24—— | −30*—— | −13—−133% | |
| Interest and finance income | 8.9—— | 2.5+188%— | 2.7—— | 2.3—— | 1.4*—— | 0.9—8.6% | |
| Other non-operating income (expense) | 8.8—— | 2.4+187%— | 2.6—— | 2.3—— | 1.4*—— | 0.9—8.5% | |
| Income tax | 0—— | 0*—— | 0*—— | 0—— | 0*—— | 0—0.0% | |
| Net income including minority interests | −113—— | −31*—— | −32*—— | −22—— | −28*—— | — | |
| Net income attributable to shareholders | −113—— | −31—— | −32—— | −22—— | −28*—— | −12—−125% | |
| Earnings per share, basic | — | -0.85—— | -0.89—— | -0.64—— | — | -8.07—— | |
| Earnings per share, diluted | — | -0.85—— | -0.89—— | -0.64—— | — | -8.07—— | |
| Shares, weighted average (basic) | 36—— | 36+2251%— | 36—— | 34—— | — | 1.5—— | |
| Shares, weighted average (diluted) | 36—— | 36+2251%— | 36—— | 34—— | — | 1.5—— | |
| Balance sheet | |||||||
| Cash and cash equivalents | 48—17.1% | 48+77.4%17.1% | 60—19.9% | 48—15.0% | 44—19.6% | 27—31.7% | |
| Short-term investments | 121—43.5% | 121+146%43.5% | 141—46.6% | 163—50.6% | 105—46.7% | 49—58.2% | |
| Other current assets | 5.9—2.1% | 5.9+0.7%2.1% | 3.5—1.1% | 4.4—1.4% | 4.3—1.9% | 5.9—7.0% | |
| Current assets | 175—62.7% | 175+113%62.7% | 204—67.6% | 216—66.9% | 153—68.2% | 82—96.9% | |
| Property, plant and equipment | 1.6—0.6% | 1.6+67.9%0.6% | 1.7—0.5% | 1.6—0.5% | 1.0—0.4% | 1.0—1.1% | |
| Right-of-use (leased) assets | 7.3—2.6% | 7.3+4433%2.6% | 7.6—2.5% | 7.9—2.5% | 1.5—0.7% | 0.2—0.2% | |
| Long-term investments | 94—33.6% | 94—33.6% | 87—28.9% | 96—29.6% | 67—30.0% | — | |
| Total assets | 278—100% | 278+229%100% | 302—100% | 322—100% | 225—100% | 85—100% | |
| Accounts payable | 9.1—3.3% | 9.1+155%3.3% | 5.0—1.7% | 4.0—1.3% | 7.8—3.4% | 3.6—4.2% | |
| Current liabilities | 20—7.4% | 20+96.6%7.4% | 17—5.8% | 11—3.3% | 18—8.0% | 10—12.3% | |
| Lease liabilities (non-current) | 6.1—2.2% | 6.1—2.2% | 6.4—2.1% | 6.8—2.1% | 1.3—0.6% | 0—0.0% | |
| Total liabilities | 27—9.7% | 27+152%9.7% | 24—8.1% | 18—5.6% | 19—8.6% | 11—12.6% | |
| Retained earnings | −306—−110% | −306—−110% | −275—−91.1% | −243—−75.3% | −221—−98.3% | −193—−228% | |
| Shareholders' equity | 251—90.3% | 251—90.3% | 278—91.9% | 305—94.4% | 206—91.4% | −183—−217% | |
| Total liabilities and equity | 278—100% | 278+229%100% | 302—100% | 322—100% | 225—100% | 85—100% | |
| Shares outstanding | 36—— | 36+2240%— | 36—— | 36—— | 32—— | 1.6—— | |
| Cash-flow statement | |||||||
| Depreciation and amortization | 0.6—— | 0.2+100%— | 0.2—— | 0.1—— | 0.1*—— | 0.1—1.0% | |
| Share-based compensation | 17—— | 4.4+689%— | 4.6—— | 3.5—— | 4.2*—— | 0.6—5.6% | |
| Cash from operating activities | −90—— | −26*—— | −20*—— | −28—— | −17*—— | — | |
| Capital expenditure | −0.6—— | −0.2*—— | −0.2*—— | −0.1—— | −0.1*—— | — | |
| Cash from investing activities | −164—— | 13*—— | 31*—— | −85—— | −123*—— | — | |
| Cash from financing activities | 275—— | 0.1*—— | 0.5*—— | 117—— | 157*—— | — | |
| Change in cash | 21—— | −12*—— | 12*—— | 4.2—— | 17*—— | — | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at Evommune, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Material agreement 2 · Unregistered share sale 2 · Bylaws or fiscal year changed 1 · Shareholder vote 1 · Results announced 5
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Bylaws or fiscal year changed | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
4 private funding rounds before listing
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Discuss Evommune, Inc.#
2 automatic updates and 0 member comments. Sign in to comment and react.
- Results announced on 12 November 2026automatic update · Nov 12, 2026
Evommune, Inc. announced results on 12 November 2026 (SEC Form 8-K, item 2.02). For the quarter ended 30 September 2026: a net loss of $31 million.
- Mutual funds: 100 funds hold $84 millionautomatic update · Jul 31, 2026
100 mutual funds in 1 country hold shares of Evommune, Inc. worth $84 million, about 15.0% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 79 funds added shares and 11 sold; on balance they bought $19 million. Share splits are not counted as trading.
How Evommune, Inc. compares in Biotechnology
- Market cap$282 M · higher than 50% of 726
- Revenue$13 M · higher than 46% of 647
- Net margin-529.8% · higher than 12% of 408
- Revenue growth85.7% · higher than 80% of 438
- Price / sales21.7× · lower than 30% of 339
- Price / book1.4× · lower than 70% of 534
- FCF yield-27.2% · higher than 36% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Evommune, Inc.🇺🇸 | $282 M | — | -529.8% | +85.7% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Evommune, Inc.? Verify and update this profile — free
Show Evommune, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.